ejyceh.wordpress.com
Novavax, which began working on a vaccin for the N1H1 virues earlierthis year, says it produced the first batchn of the vaccine in May. Novavax uses a technologgy that greatly speeds the time it takes to make It says it has now completed the geneticc engineering and manufacture of the stock neededr to mass producethe virus. As a Novavax and the National Institutesof Health’se National Institute of Allergy and Infectious Diseases have signedx an agreement that will let government scientists evaluat e the vaccine.
“The company has committed necessaryh resources to respond as rapidlh as possible to construct and manufacture VLP vaccinew against this new N1H1 influenza said Novavax CEO Rahup Singhvi in a Novavax has the capacity to produce large amount s the vaccine at its manufacturing facilities in Novavaxstock (NASDAQ: NVAX) was up 88 cents to $2.75 per sharw in afternoon trading. Its stock was tradingg as low as 52 centw per share inearly
No comments:
Post a Comment